|Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma|
BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NB Dahir, ...
Journal of clinical oncology: official journal of the American Society of …, 2015
|Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t (4; 14) and t (11; 14) myeloma|
BA Walker, CP Wardell, L Melchor, S Hulkki, NE Potter, DC Johnson, ...
Blood 120 (5), 1077-1086, 2012
|Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms|
BA Walker, CP Wardell, L Melchor, A Brioli, DC Johnson, MF Kaiser, ...
Leukemia 28 (2), 384, 2014
|Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma|
L Melchor, A Brioli, CP Wardell, A Murison, NE Potter, MF Kaiser, ...
Leukemia 28 (8), 1705, 2014
|Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma|
MF Kaiser, DC Johnson, P Wu, BA Walker, A Brioli, F Mirabella, ...
Blood 122 (2), 219-226, 2013
|APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma|
BA Walker, CP Wardell, A Murison, EM Boyle, NM Dahir, PZ Proszek, ...
Nature communications 6, 6997, 2015
|Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes|
L Melchor, E Honrado, MJ Garcia, S Alvarez, J Palacios, A Osorio, ...
Oncogene 27 (22), 3165, 2008
|The complex genetic landscape of familial breast cancer|
L Melchor, J Benítez
Human genetics 132 (8), 845-863, 2013
|The impact of intra‐clonal heterogeneity on the treatment of multiple myeloma|
A Brioli, L Melchor, M Cavo, GJ Morgan
British journal of haematology 165 (4), 441-454, 2014
|A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation|
S Alvarez, R Diaz-Uriarte, A Osorio, A Barroso, L Melchor, MF Paz, ...
Clinical Cancer Research 11 (3), 1146-1153, 2005
|Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes|
L Melchor, LP Saucedo-Cuevas, I Muñoz-Repeto, SM Rodríguez-Pinilla, ...
Breast cancer research 11 (6), R86, 2009
|An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes|
L Melchor, J Benítez
Carcinogenesis 29 (8), 1475-1482, 2008
|Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families|
E Honrado, A Osorio, RL Milne, MF Paz, L Melchor, A Cascon, M Urioste, ...
Modern Pathology 20 (12), 1298, 2007
|Analysis of myelodysplastic syndromes with complex karyotypes by high‐resolution comparative genomic hybridization and subtelomeric CGH array|
A Martínez‐Ramírez, M Urioste, L Melchor, D Blesa, L Valle, ...
Genes, Chromosomes and Cancer 42 (3), 287-298, 2005
|Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations|
C Pawlyn, L Melchor, A Murison, CP Wardell, A Brioli, EM Boyle, ...
Blood 125 (5), 831-840, 2015
|Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome|
A Brioli, H Giles, C Pawlyn, JP Campbell, MF Kaiser, L Melchor, ...
Blood 123 (22), 3414-3419, 2014
|A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers|
A Osorio, B Martínez‐Delgado, M Pollan, M Cuadros, M Urioste, ...
Human mutation 27 (3), 242-248, 2006
|Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer|
L Melchor, E Honrado, J Huang, S Álvarez, TL Naylor, MJ García, ...
Clinical Cancer Research 13 (24), 7305-7313, 2007
|Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models|
L Melchor, G Molyneux, A Mackay, FA Magnay, M Atienza, H Kendrick, ...
The Journal of pathology 233 (2), 124-137, 2014
|The spectrum and clinical impact of epigenetic modifier mutations in myeloma|
C Pawlyn, MF Kaiser, C Heuck, L Melchor, CP Wardell, A Murison, ...
Clinical Cancer Research 22 (23), 5783-5794, 2016